Pharmaceuticals, Biotechnology and Life Sciences
These data support the potential of our HPK1 inhibitor to alter the tumor microenvironment to halt cancer’s immune evasion, which we think could be a powerful tool in today’s immuno-oncology arsenal.
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nimbus Therapeutics, a biotechnology company applying deep computational expertise throughout drug discovery and development, today announced that it…
Research published in Nature utilizes cryo-EM to determine structure of critical metabolic protein CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nimbus Therapeutics, a biotechnology company…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nimbus Therapeutics, a biotechnology company applying deep computational expertise throughout drug discovery and development, today announced the addition…